Tevogen CEO Reaffirms Commitment to Closing Information Gap on Multi-Billion-Dollar Assets After Release of Revenue Projections

Tevogen Bio, a clinical-stage specialty immunotherapy biotech company based in Warren, N.J., recently announced plans to provide shareholders with an update on the valuation of its multi-billion-dollar assets. This follows a significant revenue potential announcement exceeding $1 billion. The company's CEO, Ryan Saadi, emphasized the importance of transparency with shareholders, highlighting the commitment to closing the information gap to protect their interests.

Tevogen Bio, traded under the Nasdaq symbol TVGN, is focused on developing off-the-shelf, genetically unmodified T cell therapeutics aimed at treating infectious diseases and cancers. The company's pipeline includes various promising projects:

- TVGN 489: This therapy targets SARS-CoV-2 infections in patients with B cell hematologic cancer, other cancers, rheumatoid arthritis, psoriatic arthritis, and Long COVID.
- TVGN 920: Aimed at cervical cancer prevention.
- TVGN 930: Targets EBV-associated lymphomas.
- TVGN 960: Focused on mouth and throat cancers.
- TVGN 601: Developed for multiple sclerosis.

Since its foundation in June 2020, Tevogen Bio has achieved significant milestones. The company launched its proprietary ExacTcell technology, designed to create accessible and disease-specific cellular immunotherapies. By 2022, Tevogen had been granted three U.S. patents, with nine additional patents pending, including two related to artificial intelligence, and 12 international applications. Notably, Tevogen Bio was recognized as the highest valued biotech unicorn of 2022 with an independent valuation of $4.2 billion.

In 2023, the company announced positive proof-of-concept clinical trial results for TVGN 489, a CD8+ T cell therapy for high-risk SARS-CoV-2 patients. The trial reported no dose-limiting toxicities or significant adverse events and demonstrated a rapid reduction of viral load, showcasing the therapy's potential.

Tevogen Bio also introduced Tevogen.AI to develop artificial intelligence solutions aimed at enhancing patient accessibility and accelerating innovation while reducing operational costs. Recently, Tevogen.AI joined the Microsoft for Startups program, gaining access to resources and expertise from a leading AI company.

In February 2024, Tevogen Bio marked its public debut by ringing the Nasdaq Opening Bell, celebrating its first day of trading on the public market. The company has since been included in the Russell 3000® Index, reflecting its growing influence in the biotech industry.

On the intellectual property front, Tevogen Bio has made substantial progress. The United States Patent and Trademark Office (USPTO) granted the company three patents between December 2021 and January 2022 for Covid-19 Peptide Specific T-Cells and Methods of Treating and Preventing Covid-19. Additionally, in June 2022, a Patent Cooperation Treaty (PCT) application covering Virus Specific T-Cells and Methods of Treating and Preventing Viral Infections was published, entering the National Stage in several countries, including the US, Australia, Canada, Europe, Hong Kong, and Japan.

In February 2023, another PCT application was published, covering Methods for Developing CD3+CD8+ Cells Against Multiple Viral Epitopes for the treatment of viral infections, including variants evolving to escape previous immunity. This application has entered the National Stage in numerous countries, including the US, Australia, Canada, Europe, Japan, Qatar, Saudi Arabia, and the United Arab Emirates.

Tevogen Bio also had two provisional patent applications by December 2023 for leveraging artificial intelligence to expedite target detection and accelerate product development. As of September 2024, the company has filed applications for Antigen-Specific T Cell Receptor Engineered T Cells (TCR-T) and methods of treating cancer, as well as for targeting tumor cell expression of viral antigen with stealth liposome or antibody and subsequent elimination with viral-specific CTLs.

Through these endeavors, Tevogen Bio continues to position itself as a leader in the biotech industry, with a strong focus on innovation and patient-centric solutions.